Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
Florian Heeb is a postdoctorate, researching sustainable finance, impact investing, ESG, carbon markets.
We push the boundaries of finance to solve complex problems and fuel progress in the world through the MIT finance ecosystem – a unique global network of people, programs, research, and partnerships.
By
Shayna Harris (MBA '11) has worked for nearly two decades developing sustainable food strategies, leading transformation, and making people’s lives better worldwide.
MIT Sloan has hundreds of seminars every semester bringing in the world’s leading experts on topics from sustainability to finance. Find out more.
Researchers launched an in-house Data Science and Artificial Intelligence (DSAI) challenge to beat MIT’s machine-learning models for predicting clinical trial outcomes. The results are now available.
By
The project is charting a course toward more rigorous, coherent methods for ESG integration, with four key goals that are relevant to asset owners and managers, as well as regulators.
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
By
A new study led by MIT Sloan Prof. Andrew W. Lo finds that borrowing ideas and tools from the gaming community can improve online teaching techniques and improve learning outcomes for students.
